Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics is viewed favorably because its lead PRMT5 strategy is advancing with multiple near-term catalysts, including updated vopimetostat data at ESMO 2026, initial lung cancer and GBM readouts in 2H26, and a planned Phase 3 design for 1L PDAC. The company’s fundamentals are supported by 2Q26 net earnings of $0.37 per share versus an expected $0.30, and roughly $1B in cash, cash equivalents, and marketable securities, which may fund operations potentially into profitability. Investor confidence is further reinforced by the 92% ORR and 90% 6-month PFS previously reported in 12 2L/3L PDAC patients, plus a differentiated safety profile and unusually heavy short interest that could amplify upside if clinical results hold.

Tango Therapeutics is burdened by a high-risk clinical profile, since approval for vopimetostat in 2L MTAP-del pancreatic cancer depends on a convincing overall survival benefit and could be delayed by FDA concerns over follow-up, the control arm, or broader agency disruptions. The company also faces meaningful funding pressure because its clinical programs require significant capital, raising the likelihood of dilutive equity raises, debt financing, and shareholder dilution if cash needs outpace internal resources. Competitive risk is likewise elevated, as PRMT5 inhibitors from China and new oncology mechanisms could emerge in pancreatic and lung cancer, threatening future commercialization and limiting revenue potential.